0000000000018706
AUTHOR
Carmelo Carlo Arcara
Factor V Leiden but not prothrombin G20210A mutation is a risk factor for thrombosis in patients with lymphoproliferative disease
A phase II study of capecitabine oxaliplatin chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes
Optimal duration of antithrombotic therapy in carcer patients with deep vein thrombosis: the role of residual vein thrombosis. the cancer dacus
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
Background: The clinical significance of the circulating levels of activin A and matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) was investigated in patients with breast cancer (BC) or prostate cancer (PC) with (M1) or without (M0) bone metastasis. Patients and Methods: MMP-2, MMP-9 and activin A blood concentrations were measured by enzyme immunoassays in 79 cancer patients and in 57 healthy blood donors (HS) who served as a control group. The diagnostic accuracy of these molecules to discriminate between M0 and M1 patients was evaluated by the receiver operating characteristic curve (ROC) and compared to that of tumor markers CA15.3 or prostate-specific antigen (PSA). Results: Activin A…
Eribulin Mesylate for the Treatment of Metastatic Hormone-refractory and Triple-negative Breast Cancer: A Multi-institutional Real-world Report on Efficacy and Safety
Objective Eribulin mesylate (EM) is a fully synthetic macrocyclic ketone analogue of the marine natural product halichondrin. EM has been reported to be active in metastatic breast cancer. In this paper, we report efficacy and safety of data of EM in a retrospective, real-world series of patients with poor prognosis, hormone-refractory, or triple-negative metastatic breast cancer. Materials and methods The analysis was carried out at 4 interrelated oncology centers. EM was delivered at the dose of 1.4 mg/m2 in 100 mL of normal saline over 2 to 5 minutes on days 1 and 8 every 21 days. EM was continued until disease progression or unacceptable toxicity. Side effects were reported every cycle …
Zoledronic acid-induced variations in MMP-2, MMP-9 and uPA plasma concentrations in patients with metastatic bone disease
A phase 2 study of Oxaliplatin ( O ) – Capecitabine( C ) chemotherapy in metastatic breast cancer ( MBC ) patients pretreated with Anthracyclines and taxanes VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma
We carried out a phase II nonrandomized study to examine the level of activity of oxaliplatin, pegylated liposomal doxorubicin, and cyclophosphamide in a patient population with relapsed ovarian cancer pretreated with platinum derivatives and paclitaxel. Patients received oxaliplatin (85 mg/m2), pegylated liposomal doxorubicin (30 mg/m2), and cyclophosphamide (750 mg/m2). A total of 49 patients (39 assessable for toxicity and response) were enrolled in this trial. Neutropenia grade 3 was observed in six patients (15%) and anemia grade 3 in one patient (0.2%). Fatigue grade 1–2 occurred in 26 patients (66%), nausea/vomiting grade 1 in 23 patients (58%), and alopecia grade 1–2 in 19 patients …
Low dose oral chemotherapy for hormone refractory prostate carcinoma estramustine phosphate versus estramustine phosphate and etoposide. A Randomized phase II study of GSTU foundation
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer
The use of somatostatin analogues in metastatic hormone refractory and chemo resistant prostate cancer with neuroendocrine differentiation.
A case report of inflammatory pseudotumor of the liver
Deep vein thrombosis and pulmonary embolism can be treated at home in cancer patients
Pegylated Liposomal Doxorubicin and weekly paclitaxel as first line treatment in metastatic breast cancer
New potential circulating markers for the therapeutic monitoring of metastatic bone disease.
A case of guillain-barre syndrome in a patient with non small cell lung cancer treated with chemotherapy
Guillain-Barré Syndrome (GBS) is a demyelinating polyneuropathy of probable autoimmune pathogenesis characterized by rapidly progressive symmetric paralysis. In the literature some cases of GBS associated with anticancer chemotherapy are reported. We present a case of a 55-year old woman who complained of progressive motor deficit in four limbs, areflexia in lower limbs and facial nerve paralysis one week after beginning cisplatin-gemcitabine chemotherapy for metastatic lung cancer. The cerebrospinal fluid analysis showed a strong positive Pandy reaction with 435 mg/dl total protein. The electromyography and the electroneuronography established the diagnosis of inflammatory demyelinating po…
Managing cancer patients with acute venous thromboembolism: exploring safe alternatives to hospitalisation
Acute venous thromboembolism (VTE) is a common and potentially fatal complication that frequently occurs in cancer patients. Few data are currently available about the optimal management of this category of high-risk patients. In clinical practice, physicians have to deal with many problems related to cancer patients with acute VTE. For instance, cancer patients with deep vein thrombosis (DVT) are frequently admitted to the hospital since their high rate of recurrent thrombotic events and/or bleeding-related therapy; however, most of them would prefer alternatives to prolonged hospitalisation. Then, it is not clearly whether data coming from a non-cancer population (such as that regarding t…